Conventional accounts treat the patent as a bargain between an inventor and the public: in exchange for disclosing how an invention works, the inventor receives a temporary monopoly that rewards the costly act of innovation. On this reading, the more vigorously firms patent, the more innovation society should expect, since stronger protection raises the payoff to inventing.

A growing body of analysis complicates this picture. Researchers who have examined patenting in fields such as semiconductors and software observe that firms in these industries frequently amass large portfolios of patents not to protect any single breakthrough but to build defensive thickets. The strategic value of such a portfolio lies less in any one patent's commercial worth than in its bargaining power: a firm with a thick portfolio can credibly threaten to countersue any rival that sues it, and the two firms then cross-license their portfolios and call a truce. Under this dynamic, patents function as bargaining chips in a standoff among incumbents rather than as rewards for discrete inventions.

The analysts are careful, however, not to claim that this pattern holds everywhere. In pharmaceuticals, where a single patent can map cleanly onto a single, enormously expensive-to-develop compound, the conventional reward story remains largely intact; there, robust patent protection does appear to underwrite the heavy investment required to bring a drug to market. The complication these analysts raise, then, is not that patents never reward innovation, but that in industries where products draw on hundreds of overlapping patented components, aggressive patenting can devolve into a defensive arms race that fences off entrants and channels resources into litigation rather than invention.